Mechanistically, we also found that FZKA inhibited growth of NSCLC cells through AMP-activated protein kinase alpha- (AMPKα-) mediated induction and interplay of insulin-like growth factor (IGF) binding protein 1 (IGFBP1) and forkhead homeobox type O3a (FOXO3a), demonstrating definite therapeutic effect in lung cancer [11]. Here, FOXO3 is linked to non-small cell lung carcinoma.